✦ LIBER ✦

A Mathematical Model of Breast Cancer Treatment with CMF and Doxorubicin

✍ Scribed by Rachel Roe-Dale; David Isaacson; Michael Kupferschmid

Book ID: 107386159
Publisher: Springer
Year: 2010
Tongue: English
Weight: 821 KB
Volume: 73
Category: Article
ISSN: 1522-9602
DOI: 10.1007/s11538-010-9549-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant treatment of breast cancer: A p

Adjuvant treatment of breast cancer: A pilot immunochemotherapy study with CMF, interleukin-2 and interferon alpha

✍ Giuseppe Tonini; Corrado Nunziata; Salvatore P. Prete; Rita Pepponi; Mario Turri 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 300 KB

Vincristine, doxorubicin and mitomycin (

Vincristine, doxorubicin and mitomycin (VAM) in patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate and fluorouracil (CMF)

✍ Sharon K. Shipp; Hyman B. Muss; Mary Alice Westrick; M. Robert Cooper; V. Jackso 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 383 KB

Thirty-six evaluable patients with advanced breast cancer who had failed prior CMF therapy [15 (42%) as adjuvant treatment and 21 (58%) for advanced disease] were treated with a combination of vincristine, doxorubicin, and mitomycin (VAM). There was one CR and 10 PR, giving a response rate of 31% (P

A randomised factorial trial of sequenti

A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer

✍ De Placido, S; De Laurentiis, M; De Lena, M; Lorusso, V; Paradiso, A; D'Aprile, 📂 Article 📅 2005 🏛 Nature Publishing Group 🌐 English ⚖ 129 KB

Typhlitis resulting from treatment with

Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer

✍ Bernhard C. Pestalozzi; George A. Sotos; Peter L. Choyke; Jason S. Fisherman; Ke 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 381 KB 👁 2 views

## Background. Typhlitis is being recognized with in- creasing frequency as a serious complication of aggressive chemotherapy for hematologic and solid malignancies. In this report the authors describe two cases of typhlitis in patients with metastatic breast cancer treated with taxol and doxorub

Chronopharmacokinetics of doxorubicin in

Chronopharmacokinetics of doxorubicin in patients with breast cancer

✍ P. Canal; A. Sqalli; M. Forni; C. Chevreau; A. Pujol; R. Bugat; H. Roche; J. Ous 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 543 KB

The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy including DOX (50 mg/m2 as an iv bolus), given at two different times (09.00 h or 21.00 h). The two randomized courses of the protocol were given to each

Combined modality treatment of locally a

Combined modality treatment of locally advanced breast cancer: Adjuvant combination chemotherapy with and without doxorubicin

✍ Ephraim S. Casper; Carol A. Guidera; George J. Bosl; Thomas B. Hakes; Richard J. 📂 Article 📅 1987 🏛 Springer US 🌐 English ⚖ 552 KB